サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753023

皮膚がん治療薬の世界市場

Skin Cancer Drugs

出版日
ページ情報
英文 483 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.50円
皮膚がん治療薬の世界市場
出版日: 2025年06月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 483 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

皮膚がん治療薬の世界市場は2030年までに137億米ドルに達する見込み

2024年に92億米ドルと推定される皮膚がん治療薬の世界市場は、2024～2030年の分析期間においてCAGR 6.8%で成長し、2030年には137億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法薬は、CAGR 7.0%を記録し、分析期間終了時には53億米ドルに達すると予測されます。標的治療薬セグメントは、分析期間中にCAGR 8.3%の成長が見込まれます。

米国市場は25億米ドルと推定、中国はCAGR 10.7％で成長予測

米国の皮膚がん治療薬市場は、2024年には25億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに28億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4％と6.6％と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界の「皮膚がん治療薬」市場- 主要動向と促進要因のまとめ

なぜ皮膚がん治療薬市場は世界的に需要が急増しているのか？

皮膚がんの世界の負担は過去10年間で劇的に増加しており、新規かつ効果的な皮膚がん治療薬に対するこれまでにない需要が喚起されています。メラノーマ以外の皮膚がん（基底細胞がん、扁平上皮がんを含む）および悪性黒色腫は、年間150万人以上が新たに診断され、がん関連ヘルスケア費用の主要な原因となっています。長時間の紫外線曝露、人口の高齢化、環境の悪化、遺伝的感受性などの要因が、特に北米、欧州、オーストラリアなどの地域で、世界の罹患率の上昇につながっています。早期発見をめぐる社会的意識の高まりは、広範な検診キャンペーンと相まって、診断症例数の増加にもつながっており、その結果、薬剤を用いた介入の対象となる患者層が拡大しています。皮膚がんの中で最も致死率の高いメラノーマは、転移の可能性が高く、これまで治療選択肢が限られていたため、治療パラダイムに変化が生じています。その結果、製薬企業はオンコロジー・パイプラインの中で皮膚がんを優先するようになり、FDAやEMAによる標的治療薬や免疫治療薬の承認が急増しました。政府および保険業者もまた、疾病負担の増加により高額の治療費に対する保険適用を拡大し始め、より公平なアクセスを生み出しています。罹患率と診断率の両方が着実に上昇する中、外用剤から高度な生物学的製剤に至るまで、治療の選択肢に対する需要は、がん治療のエコシステムを再構築しつつあります。

標的治療と免疫腫瘍学は皮膚がん治療をどのように再定義しているのか？

皮膚がんの治療法は、標的治療薬と免疫腫瘍薬の台頭によってパラダイムシフトを起こしました。化学療法や外科的切除といった従来の治療アプローチは、精密医療戦略によって補完されたり、取って代わられたりすることが多くなっています。50％近くの症例に見られるBRAF遺伝子変異を有するメラノーマ患者に対しては、BRAF阻害剤（ベムラフェニブやダブラフェニブなど）とMEK阻害剤（トラメチニブなど）の併用が標準治療となり、無増悪生存期間と全生存期間の有意な改善を示しています。一方、PD-1阻害剤（ニボルマブ、ペムブロリズマブ）やCTLA-4遮断剤（イピリムマブ）などのチェックポイント阻害剤は、免疫系ががん細胞をより効果的に攻撃できるようにすることで、進行期メラノーマの治療成績に革命をもたらしました。これらの薬剤は、メルケル細胞がんや進行性皮膚扁平上皮がんなど、メラノーマ以外の皮膚がんにおいても有望視されています。併用治療、個別化ワクチン、T細胞ベースの治療が、技術革新の次の波として浮上しています。さらに、局所免疫応答モジュレーター（イミキモドのような）やヘッジホッグ経路阻害剤（vismodegib、sonidegib）は、限局例や再発例に効果的な選択肢を提供しています。分子診断学とコンパニオン診断学の進歩は、より良い患者層別化と標的治療を可能にし、有効性を向上させながら毒性を最小限に抑えています。このような画期的な治療法は、生存期間を延長するだけでなく、生活の質（QOL）を向上させ、皮膚がんを最もダイナミックに進化しているがん領域のひとつにしています。

どのような市場勢力とヘルスケア動向が皮膚がん治療薬の採用を加速させているか？

マクロ経済およびヘルスケア特有のいくつかの動向が、先進国市場および新興国市場の双方で皮膚がん治療薬の採用を加速させています。特にがん領域における医療費の増加は、高価な生物学的製剤や分子標的薬の急速な普及を可能にしています。製薬会社は研究開発に多額の投資を行い、戦略的提携を結んで、特に免疫療法と遺伝子編集における新規薬剤の開発を急ピッチで進めています。FDAやEMAのような規制機関による早期承認パスウェイ、希少疾病用医薬品の指定、画期的治療タグの導入は、皮膚がん治療薬の市場投入までの時間を大幅に短縮しています。償還の枠組みが強化され、価値ベースの価格設定モデルが採用されつつあることで、高コストの医薬品がより利用しやすくなっています。デジタルヘルスツールや遠隔皮膚科は、早期発見と迅速な治療開始を可能にし、薬物治療の対象となる患者層をさらに拡大しています。臨床ガイドラインでは、新規薬剤を第一選択薬として取り入れる傾向が強まっており、その有効性を反映して、処方者は先進的な治療法を好むようになっています。さらに、患者アドボカシー、臨床試験の認知度向上、消費者への医薬品直接販売の増加（特に高所得国）により、革新的な治療を熱望する情報通の患者層が形成されています。また、医薬品の世界化と医薬品流通経路の改善により、以前は十分なサービスを受けていなかった市場にも先進的治療法がもたらされています。これらの複合的な力によって、皮膚がん治療薬市場は急速に拡大し、患者中心の革新的ながん領域へと変貌を遂げつつあります。

世界の皮膚がん治療薬市場の成長を促進する要因は何か？

皮膚がん治療薬市場の成長は、医学、患者ケアモデル、業界力学の進歩に関連する、いくつかの特定の相互関連要因によって牽引されています。第一に、メラノーマと非メラノーマ皮膚がんの世界の罹患率の上昇（紫外線曝露、ライフスタイルの変化、高齢化などが要因）により、治療対象患者層が拡大しています。第二に、標的治療薬（BRAF/MEK阻害剤など）や免疫腫瘍学（PD-1/PD-L1阻害剤、CTLA-4阻害剤など）における大きな技術的ブレークスルーが、臨床転帰を改善し、新たな治療基準を設定しつつあります。第三に、世界の製薬大手やバイオテクノロジー企業によるがん研究開発パイプラインへの投資拡大が、細胞療法、二重特異性抗体、RNAベースの薬剤を含む次世代治療薬の開発を促進しています。第四に、迅速な承認プロセス、希少疾病用医薬品（オーファンドラッグ）優遇措置、適応試験デザインといった形での規制当局の支援が、医薬品の迅速な商業化を促しています。第五に、分子診断とバイオマーカースクリーニングの利用可能性が高まることで、精密治療戦略が可能となり、治療効果の向上と副作用の最小化が期待されます。第6に、有利なヘルスケア償還政策と公的および民間支払者による腫瘍治療薬の採用増加により、高コストの治療に対する患者のアクセスが向上しています。第7に、拡大する患者教育、デジタル関与ツール、遠隔医療プラットフォームが、早期診断と積極的な治療決定を促進しています。最後に、新興市場がヘルスケアのインフラを強化し、専門的な腫瘍学治療へのアクセスを拡大することで、新たな成長路線が生まれています。こうした非一般的な要因の積み重ねが、皮膚がん治療薬市場の持続的な世界的成長を促し、医薬品・がん領域で最もダイナミックに拡大している分野の一つとなっています。

セグメント

薬剤タイプ（化学療法薬、標的治療薬、免疫療法薬、ホルモン療法薬、その他の薬剤タイプ）、がんタイプ（基底細胞がん、扁平上皮がん、黒色腫、その他のがんタイプ）、投与経路（局所、経口、注射、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全42件）

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35764

Global Skin Cancer Drugs Market to Reach US$13.7 Billion by 2030

The global market for Skin Cancer Drugs estimated at US$9.2 Billion in the year 2024, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Chemotherapy Drugs, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Targeted Therapy Drugs segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 10.7% CAGR

The Skin Cancer Drugs market in the U.S. is estimated at US$2.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 10.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global "Skin Cancer Drugs" Market - Key Trends & Drivers Summarized

Why Is The Skin Cancer Drug Market Experiencing A Surge In Global Demand?

The global burden of skin cancer has intensified dramatically over the past decade, catalyzing an unprecedented demand for novel and effective skin cancer drugs. With over 1.5 million new cases diagnosed annually, non-melanoma skin cancers (including basal cell carcinoma and squamous cell carcinoma) and malignant melanoma have become leading contributors to cancer-related healthcare costs. Factors such as prolonged UV exposure, aging populations, environmental degradation, and genetic susceptibility have led to rising incidence rates worldwide, particularly in regions like North America, Europe, and Australia. The increasing public awareness surrounding early detection, combined with widespread screening campaigns, has also led to a higher number of diagnosed cases - thereby expanding the patient pool for drug-based interventions. Melanoma, the deadliest form of skin cancer, has seen a shift in treatment paradigms due to its high metastatic potential and historically limited treatment options. As a result, pharmaceutical companies have prioritized skin cancer in their oncology pipelines, leading to a surge in FDA and EMA approvals for targeted and immunotherapeutic agents. Governments and insurance providers have also started to expand coverage for high-cost therapies due to the rising disease burden, creating more equitable access. With both incidence and diagnosis rates climbing steadily, the demand for therapeutic options - ranging from topical agents to advanced biologics - is reshaping the oncology treatment ecosystem.

How Are Targeted Therapies And Immuno-Oncology Redefining Skin Cancer Treatment?

The treatment landscape for skin cancer has undergone a paradigm shift with the rise of targeted therapies and immuno-oncology drugs. Traditional treatment approaches, such as chemotherapy and surgical excision, are increasingly being complemented or replaced by precision medicine strategies. For melanoma patients with BRAF mutations - found in nearly 50% of cases - BRAF inhibitors (like vemurafenib and dabrafenib) combined with MEK inhibitors (such as trametinib) have become the standard of care, demonstrating significant improvements in progression-free and overall survival. Meanwhile, checkpoint inhibitors - including PD-1 inhibitors (nivolumab, pembrolizumab) and CTLA-4 blockers (ipilimumab) - have revolutionized outcomes for advanced-stage melanoma by enabling the immune system to attack cancer cells more effectively. These agents have also shown promise in non-melanoma skin cancers, such as Merkel cell carcinoma and advanced cutaneous squamous cell carcinoma. Combination therapies, personalized vaccines, and T-cell-based treatments are emerging as the next wave of innovation. Moreover, topical immune response modulators (like imiquimod) and hedgehog pathway inhibitors (vismodegib, sonidegib) are offering effective options for localized and recurrent cases. Advances in molecular diagnostics and companion diagnostics are enabling better patient stratification and targeted delivery, minimizing toxicity while improving efficacy. These therapeutic breakthroughs are not only extending survival but also improving quality of life, making skin cancer one of the most dynamically evolving oncology segments.

What Market Forces And Healthcare Trends Are Accelerating Adoption Of Skin Cancer Therapies?

Several macroeconomic and healthcare-specific trends are accelerating the adoption of skin cancer drugs across both developed and emerging markets. Increasing healthcare expenditure, particularly in oncology, has created space for the rapid uptake of expensive biologics and targeted drugs. Pharmaceutical companies are investing heavily in R&D and forming strategic collaborations to fast-track the development of novel agents, especially in immunotherapy and gene editing. The introduction of accelerated approval pathways, orphan drug designations, and breakthrough therapy tags by regulatory bodies like the FDA and EMA has significantly reduced time-to-market for skin cancer drugs. Enhanced reimbursement frameworks and the growing adoption of value-based pricing models are making high-cost drugs more accessible. Digital health tools and teledermatology are enabling earlier detection and faster treatment initiation, further expanding the patient base eligible for drug therapy. Clinical guidelines are increasingly incorporating novel agents as first-line options, reflecting their efficacy and pushing prescriber preference toward advanced therapies. Moreover, the rise in patient advocacy, clinical trial awareness, and direct-to-consumer drug marketing - particularly in high-income countries - has created a more informed patient population eager for innovative treatments. Pharmaceutical globalization and improved drug distribution channels are also bringing advanced therapies to previously underserved markets. These collective forces are transforming the skin cancer drug market into a fast-expanding, patient-centered, and innovation-driven sector within oncology.

What Factors Are Driving The Growth Of The Skin Cancer Drugs Market Globally?

The growth in the skin cancer drugs market is driven by several specific and interrelated factors linked to advancements in medical science, patient care models, and industry dynamics. First, the rising global incidence of both melanoma and non-melanoma skin cancers - fueled by UV exposure, lifestyle changes, and aging populations - is expanding the treatment-eligible patient base. Second, major technological breakthroughs in targeted therapies (e.g., BRAF/MEK inhibitors) and immuno-oncology (e.g., PD-1/PD-L1 and CTLA-4 inhibitors) are improving clinical outcomes and setting new standards of care. Third, increased investments in oncology R&D pipelines by global pharmaceutical giants and biotech firms are driving the development of next-generation therapeutics, including cellular therapies, bispecific antibodies, and RNA-based drugs. Fourth, regulatory support in the form of expedited approval processes, orphan drug incentives, and adaptive trial designs is encouraging faster drug commercialization. Fifth, growing availability of molecular diagnostics and biomarker screening is enabling precision treatment strategies, thus improving therapeutic response and minimizing side effects. Sixth, favorable healthcare reimbursement policies and rising adoption of oncology drugs by public and private payers are improving patient access to high-cost treatments. Seventh, expanding patient education, digital engagement tools, and telemedicine platforms are driving earlier diagnosis and proactive treatment decisions. Lastly, emerging markets are ramping up healthcare infrastructure and access to specialized oncology care, creating new growth avenues. These cumulative, non-generic factors are catalyzing sustained global growth in the skin cancer drugs market, making it one of the most dynamically expanding sectors in the pharmaceutical and oncology space.

SCOPE OF STUDY:

The report analyzes the Skin Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs, Other Drug Types); Cancer Type (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Other Cancer Types); Administration Route (Topical, Oral, Injectable, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Skin Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Skin Cancer Globally Spurs Demand for Targeted Therapeutic Solutions
    • Advancements in Immunotherapy and Checkpoint Inhibitors Strengthen Business Case for Innovative Drug Approaches
    • Increased Skin Cancer Awareness and Early Detection Efforts Expand the Addressable Market for Treatment Drugs
    • Favorable Regulatory Approvals for Breakthrough Therapies Propel Market Entry of Novel Agents
    • Integration of Companion Diagnostics with Drug Development Drives Personalized Treatment Strategies
    • Surge in Melanoma Research Funding Accelerates Clinical Pipelines and Commercial Drug Rollouts
    • Expanding Aging Population Throws the Spotlight on High-Risk Demographics and Preventive Treatment Demand
    • Strategic Collaborations Between Pharma and Biotech Firms Enhance Access to Pipeline Candidates
    • Growth in Teledermatology and Remote Monitoring Supports Timely Drug Administration and Prescription Growth
    • Emerging Use of mRNA and Nanoparticle Delivery Systems Generates New Opportunities for Drug Innovation
    • Market Competition and Biosimilar Development Create Pricing Pressures and Regulatory Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Skin Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Skin Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Skin Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Skin Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hormone Therapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hormone Therapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hormone Therapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Basal Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Basal Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Basal Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Squamous Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • CHINA
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Skin Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Skin Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 152: UK Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Spain 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Russia 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Russia 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Skin Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Australia 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Australia 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • INDIA
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 227: India Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: India 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: India 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: South Korea 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: South Korea 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Skin Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Skin Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Latin America 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Latin America 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Argentina 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Argentina 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Brazil 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Brazil 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Mexico 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Mexico 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Skin Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Skin Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Middle East 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Middle East 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Iran 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Iran 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Israel 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Israel 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: UAE 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: UAE 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Skin Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Skin Cancer Drugs by Drug Type - Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Skin Cancer Drugs by Drug Type - Percentage Breakdown of Value Sales for Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Skin Cancer Drugs by Administration Route - Topical, Oral, Injectable and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Skin Cancer Drugs by Administration Route - Percentage Breakdown of Value Sales for Topical, Oral, Injectable and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Skin Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Africa 15-Year Perspective for Skin Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Skin Cancer Drugs by Cancer Type - Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Africa 15-Year Perspective for Skin Cancer Drugs by Cancer Type - Percentage Breakdown of Value Sales for Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma and Other Cancer Types for the Years 2015, 2025 & 2030

IV. COMPETITION